• In March 2026, Recursion Pharmaceuticals reported an expanded partnership with Citeline to integrate real-world data into its AI-enabled drug development platform, and announced that oncology veteran Vicki Goodman, M.D., will become Chief Medical Officer as of April 6, 2026, succeeding David Mauro, M.D., Ph.D.
• Together, the data partnership and leadership change highlight Recursion’s push to strengthen clinical execution, particularly in oncology, by combining advanced analytics with deep late-stage development expertise.
• Next, we’ll examine how Dr. Goodman’s oncology track record could influence Recursion’s investment narrative and expectations for its AI-driven pipeline.

Find 63 companies with promising cash flow potential yet trading below their fair value.

Recursion Pharmaceuticals Investment Narrative Recap

To own Recursion, you have to believe its AI-first approach and partnerships can eventually turn today’s large losses into a sustainable drug pipeline. The Citeline data deal and Dr. Goodman’s appointment look directionally helpful for near term clinical execution, but they do not remove the central risk around cash burn, a limited runway into late 2027, and dependence on partner and capital markets funding.

The announcement with Citeline, which integrates real world data into Recursion’s platform and has already supported faster trial enrollment, is the most directly relevant here. If that capability and Dr. Goodman’s late stage oncology experience translate into cleaner, better run studies, it could become an important supporting factor for upcoming data readouts and partnership milestones that the company relies on for revenue.

Yet beneath the promise of AI driven discovery, investors should be aware that tightening funding conditions could collide with Recursion’s still substantial cash burn and...

Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.

Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 129% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could grow about 120% a year to roughly US$804,000,000 by 2029, but views on data privacy risks and open sourced AI tools show just how differently you can assess the same news, so it is worth comparing these upbeat forecasts with more cautious takes before deciding what you believe.

Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth 36% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.